Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | FNTA | P49354 | 5/20 | 0.44 |
| ▸ | FNTB | P49356 | 5/20 | 0.44 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23922585 | 0.89 | CYP2C9 (0.62) | CYP2C9HDAC2FNTAFNTBALDH1A1 | |
| SCHEMBL18618664 | 0.87 | HDAC2 (0.62) | HDAC2FNTAFNTBPGGT1BLMNA | |
| SCHEMBL23922590 | 0.83 | HDAC2 (0.57) | HDAC2 | |
| SCHEMBL18619952 | 0.83 | FNTA (0.52) | CYP2C9HDAC2FNTAFNTBPGGT1B | |
| SCHEMBL23922597 | 0.79 | ALDH1A1 (0.43) | HDAC2ALDH1A1TSHR | |
| SCHEMBL18619712 | 0.79 | HDAC2 (0.53) | CYP2C9HDAC2FNTAFNTBPGGT1B | |
| SCHEMBL9554921 | 0.77 | FOLH1 (0.53) | FNTAFNTBPGGT1BALDH1A1GAA | |
| SCHEMBL11413338 | 0.77 | FOLH1 (0.53) | FNTAFNTBPGGT1BALDH1A1GAA | |
| SCHEMBL23922593 | 0.77 | ALDH1A1 (0.38) | HDAC2FNTAFNTBALDH1A1TSHR | |
| SCHEMBL18618668 | 0.77 | HDAC2 (0.65) | CYP2C9HDAC2FNTAFNTBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11149062-B2 | HDAC inhibitors and methods of treatment using the same | UWM RESEARCH FOUNDATION, INC. (US) | 2021-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11149062-B2 | HDAC inhibitors and methods of treatment using the same | HDAC4, HDAC2, HDAC8 | CYP2C9 4602/4885HDAC2 2/4885FNTA 4294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.